Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Fish and Richardson
US Department of Justice
Federal Trade Commission
Cantor Fitzgerald
Farmers Insurance
Chubb
Chinese Patent Office
Accenture
Covington

Generated: December 10, 2018

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR ENTEREG

« Back to Dashboard

Clinical Trials for Entereg

Trial ID Title Status Sponsor Phase Summary
NCT00256932 Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed GlaxoSmithKline Phase 3 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00256932 Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed Cubist Pharmaceuticals LLC Phase 3 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00259922 Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed GlaxoSmithKline Phase 3 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00259922 Alvimopan For The Treatment Of Constipation Due To Opioids Being Taken For Persistent Non-Cancer Pain Completed Cubist Pharmaceuticals LLC Phase 3 Adults who are taking opioid therapy for persistent non-cancer pain and have resulting opioid-induced bowel dysfunction (OBD) will be randomized (1:1:1) to one of 2 alvimopan arms, or to placebo. The primary objective of this phase 3 confirmatory study is to compare alvimopan with placebo for efficacy in the treatment of OBD. The primary efficacy endpoint is based on frequency of bowel movements. Subjects will be required to: (1) track their bowel movements and other bowel symptoms and (2) attend 6 clinic visits over 4 months.
NCT00708201 A Study of Alvimopan for the Management of Postoperative Ileus in Participants Undergoing Radical Cystectomy Completed Cubist Pharmaceuticals LLC Phase 4 This study is being conducted to determine whether alvimopan can accelerate recovery of gastrointestinal function following radical cystectomy when compared with a placebo. Secondary objectives of the study are: - to evaluate the effect of alvimopan on hospital length of stay - to evaluate the effect of alvimopan on prespecified postoperative ileus (POI)-related morbidities - to evaluate the overall and cardiovascular safety of alvimopan
NCT01143259 Intermountain Healthcare's Enhanced Recovery Protocol for Colon Surgery With and Without Alvimopan Use Completed Cubist Pharmaceuticals LLC N/A The purpose of this study is to determine if the addition of alvimopan to our care process model for colon resection patients will decrease length of stay. The care process model is a combination of optimal IV fluid management, early feeding, early ambulation, patient education, and pain management.
Trial ID Title Status Sponsor Phase Summary

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

Clinical Trial Conditions for Entereg

Condition Name

Condition Name for Entereg
Intervention Trials
Ileus 5
Constipation 3
Colorectal Surgery 2
Bowel Dysfunction 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Entereg
Intervention Trials
Ileus 5
Constipation 3
Intestinal Diseases 2
Gastrointestinal Diseases 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Entereg

Trials by Country

Trials by Country for Entereg
Location Trials
United States 92
Canada 12
Germany 8
United Kingdom 7
Australia 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Entereg
Location Trials
Ohio 4
California 4
North Carolina 4
Illinois 3
Texas 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Entereg

Clinical Trial Phase

Clinical Trial Phase for Entereg
Clinical Trial Phase Trials
Phase 4 3
Phase 3 5
Phase 2 2
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Entereg
Clinical Trial Phase Trials
Completed 7
Not yet recruiting 5
Recruiting 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Entereg

Sponsor Name

Sponsor Name for Entereg
Sponsor Trials
Cubist Pharmaceuticals LLC 7
Merck Sharp & Dohme Corp. 3
GlaxoSmithKline 3
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Entereg
Sponsor Trials
Industry 13
Other 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
US Army
QuintilesIMS
Federal Trade Commission
Merck
US Department of Justice
Deloitte
Queensland Health
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.